8,577 results match your criteria Overactive Bladder in Children
J Proteome Res 2018 Dec 12. Epub 2018 Dec 12.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with at least one-third of its patients relapsing after treatment with the current chemotherapy regimen, R-CHOP. By gene expression profiling, patients with DLBCL can be categorized into two clinically relevant subtypes: activated B-cell (ABC) and germinal center B-cell (GCB) DLBCL. Patients with the ABC subtype have a poorer prognosis than those with GCB, and are defined by chronic, overactive signaling through the B-cell receptor and NF-κB pathways. Read More
BJU Int 2018 Dec 11. Epub 2018 Dec 11.
Department of Urology, Antwerp University Hospital, Edegem, Belgium.
Objectives: To assess clinical follow-up data over 24 months using the standardized tined lead implantation technique, comparing the use of the curved vs straight stylet.
Patients And Methods: Single tertiary center, prospective study (August 2013 - June 2015) involving 40 patients with overactive bladder and 15 with non-obstructive urinary retention refractory to first-line treatment.
Primary Outcome: successful tined lead procedure; intention to treat analysis at 12 and 24 months. Read More
Arab J Urol 2018 Dec 7;16(4):391-396. Epub 2018 Aug 7.
Department of Neurosurgery, Al-Mustansiriya University, Baghdad, Iraq.
Objectives: To present our experience, in Iraq, with sacral neuromodulation (SNM) in patients with refractory lower urinary tract dysfunction, with discussion of the factors that affect the response rate.
Patients And Methods: In this prospective, clinical, interventional study, 24 patients were evaluated and treated by a team comprised of a Urologist and a Neurosurgeon with SNM over a 1.5-year period. Read More
Prog Urol 2018 Dec 4. Epub 2018 Dec 4.
Service de neuro-urologie, hôpital Tenon, AP-HP, Paris 75020, France. Electronic address:
Context: Stroke generates diverse urinary disorders, frequent but often under-diagnosed and thus untreated. Even though advances in the comprehension of the physiological voiding control and involved brain areas, the precise correspondence between lesion sites and observed urinary symptoms is not clearly established.
Objective: This review aimed to update on this neuroanatomical correlates. Read More
Cell Death Dis 2018 Dec 5;9(12):1166. Epub 2018 Dec 5.
CellCOM research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Servizo Galego de Saúde (SERGAS), Universidade da Coruña (UDC), Xubias de Arriba, 84, 15006 A, Coruña, Spain.
Osteoarthritis (OA), a chronic disease characterized by articular cartilage degeneration, is a leading cause of disability and pain worldwide. In OA, chondrocytes in cartilage undergo phenotypic changes and senescence, restricting cartilage regeneration and favouring disease progression. Similar to other wound-healing disorders, chondrocytes from OA patients show a chronic increase in the gap junction channel protein connexin43 (Cx43), which regulates signal transduction through the exchange of elements or recruitment/release of signalling factors. Read More
Fortschr Neurol Psychiatr 2018 Dec 3. Epub 2018 Dec 3.
Marien Hospital Herne, Universitätsklinikum der Ruhr- Universität Bochum, Abteilung für Neuro-Urologie.
An overactive neurogenic detrusor and an non-neurogenic overactive bladder both exhibit symptoms such as urgency and frequency, both with and without urinary incontinence, and are often accompanied by nocturia. OnabotulinumtoxinA-Detrusorinjection has become well established as a second line therapy in cases where anticholinergic medication has failed. The procedure can be performed under general or local anesthesia, in both in- and outpatient settings. Read More
J Gynecol Obstet Hum Reprod 2018 Nov 30. Epub 2018 Nov 30.
Hôpital Privé Sainte Marie, Groupe Ramsay General de Sante, Chalon sur Saône, France. Electronic address:
Introduction: Treatment of pelvic organ prolapse is an important public health issue due to the ageing population. The Food and Drug Administration, in 2011, issued a warning on complications after transvaginal insertion of high weight mesh. We evaluated a 6 tension-free straps, light prosthesis made from polypropylene monofilaments. Read More
Transl Androl Urol 2018 Dec;7(6):912-919
Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, London, UK.
Background: To evaluate safety, acceptability and pilot efficacy of transcutaneous low-frequency tibial nerve stimulation (TNS) using a novel device as home-based neuromodulation.
Methods: In this single-centre pilot study, 48 patients with overactive bladder (OAB) (24 with neurogenic and 24 with idiopathic OAB) were randomized to use a self-applicating ambulatory skin-adhering device stimulating transcutaneously the tibial nerve at 1 Hz for 30 minutes, either once daily or once weekly, for 12 weeks. Changes in OAB symptoms and QoL were measured at baseline, weeks 4, 8, and 12 using validated scoring instruments (ICIQ-OAB and ICIQ-LUTSqol), 3-day bladder diary and a Global Response Assessment (GRA) at week 12. Read More
Sex Med Rev 2018 Nov 28. Epub 2018 Nov 28.
Atlanta PT, Altanta, GA, USA.
Introduction: Many conditions of pelvic and sexual dysfunction can be addressed successfully through pelvic floor physical therapy (PFPT) through various manual therapy techniques, neuromuscular reeducation, and behavioral modifications. The field of pelvic rehabilitation, including sexual health, continues to advance to modify these techniques according to a biopsychosocial model.
Aim: To provide an update on peer-reviewed literature on the role of PFPT in the evaluation and treatment of pelvic and sexual dysfunctions in men and women owing to the overactive and the underactive pelvic floor. Read More
Maturitas 2019 Jan 22;119:21-24. Epub 2018 Oct 22.
The Royal Women's Hospital, 20 Flemington Road Parkville, Victoria 3052 Australia; The University of Melbourne, Department of Obstetrics and Gynaecology, 7thFloor Royal Women's Hospital, 20 Flemington Road Parkville, Victoria 3052 Australia. Electronic address:
Botulinum toxin, from the bacteria Clostridium botulinum, acts by block the pre-synaptic release of acetylcholine at the neuromuscular junction, resulting in temporary muscle paralysis. There are several clinically available formulations, the most extensively studied being of onabotulinumtoxinA. This article outlines three of the common clinical applications of onabotulinumtoxinA relevant to women's health: the management of symptoms of overactive bladder, chronic migraine and facial lines. Read More
Eur J Pharmacol 2018 Nov 28;843:240-250. Epub 2018 Nov 28.
Dong-A ST Research Institute, Yongin 17073, Republic of Korea.
Several antimuscarinics have been commonly used for overactive bladder patients, but dry mouth as a major anticholinergic side effect remains a shortcoming to limit long-term use. The aim of this study was to elucidate the pharmacological properties of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland. DA-8010 exhibited a high binding affinity for human muscarinic M receptor with pK of 8. Read More
Gynecol Obstet Fertil Senol 2018 Nov 27. Epub 2018 Nov 27.
Département de gynécologie, hôpital femme-mère-enfant (HFME), hospices civils de Lyon, 59, boulevard Pinel, 69000 Lyon, France; EMR 3738, université Claude-Bernard Lyon 1, 69000 Lyon, France. Electronic address:
Neurourol Urodyn 2018 Dec 4. Epub 2018 Dec 4.
Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Urinary incontinence is a prevalent condition worldwide and causes a tremendous impact on a woman's quality of life. While conservative and non-surgical therapies are options for treatment, surgery for stress urinary incontinence (SUI) is common. Options include colposuspension, slings (pubovaginal and midurethral), and periurethral bulking. Read More
J Comp Eff Res 2018 Dec 4. Epub 2018 Dec 4.
Department of Urology, Mount Sinai Hospital, 625 Madison Avenue, New York, NY, 10022, USA.
Aim: To assess the cost-effectiveness of onabotulinumtoxinA (onabotA), implantable sacral nerve stimulation devices, percutaneous tibial nerve stimulation, anticholinergic medications and mirabegron compared with best supportive care (BSC) for management of refractory overactive bladder (OAB).
Methods: A Markov model was developed to compare the cost-effectiveness of treatment options with BSC over a 10-year time horizon. Resource utilization, discontinuation rates and costs were derived from unpublished and published sources. Read More
BJS Open 2018 Dec 28;2(6):364-370. Epub 2018 May 28.
Department of Ear, Nose and Throat, Head and Neck Surgery St George's Hospital London UK.
Background: The majority of patients with primary hyperparathyroidism (PHPT) have a single overactive adenoma. Advances in preoperative imaging and surgical adjuncts have given rise to minimally invasive parathyroidectomy (MIP), with lower complication rates in comparison with bilateral neck exploration. Misdiagnosis and undertreatment of multiglandular disease, leading to potentially higher recurrence rates, remains a concern. Read More
Neurourol Urodyn 2018 Nov 29. Epub 2018 Nov 29.
Department of Urology, Ghent University Hospital, Ghent, Belgium.
Aims: To report the initial clinical experience with selective bladder denervation (SBD) of the trigone in women with refractory overactive bladder (OAB).
Methods: Females with refractory OAB underwent SBD of the bladder sub-trigone region. Patients were treated using a 10-s voltage-controlled radiofrequency (RF) algorithm (RF10) at study onset. Read More
Int Urogynecol J 2018 Nov 29. Epub 2018 Nov 29.
Division of Urogynecology, NorthShore University HealthSystem, University of Chicago Pritzker School of Medicine, 9650 Gross Point Road, Suite 3900, Skokie, IL, 60076, USA.
Introduction And Hypothesis: Multiple publications have demonstrated the efficacy of percutaneous tibial nerve stimulation (PTNS) for overactive bladder syndrome (OAB). However, patient characteristics associated with successful treatment have not been well established. The aim of this study was to identify prognostic factors for successful PTNS treatment. Read More
Stem Cell Investig 2018 31;5:39. Epub 2018 Oct 31.
Department of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA, USA.
Breast cancer is a heterogeneous disease that accounts for 30% of all cancers diagnosed in women and over half a million deaths per year. Cancer stem cells (CSCs) make up a small subpopulation of cells within a tumor, are capable of self-renewal and, are responsible for tumor initiation, formation, and recurrence. Breast CSCs (BCSCs) have been the subject of concentrated research as potential targets for breast cancer therapies. Read More
Epidemiology 2018 Nov 27. Epub 2018 Nov 27.
RTI Health Solutions, Barcelona, Av. Diagonal, 605, 9-1, 08028 Barcelona, Spain.
Cell Calcium 2018 Nov 17;77:8-19. Epub 2018 Nov 17.
Department of Urology, the Fourth Affiliated Hospital of China Medical University, No.4, Chong-shan East Road, Shenyang 110032, Liaoning Province, PR China. Electronic address:
Purpose: It has been suggested that FK506 could improve some symptoms of OAB in both clinical settings and animal models; however, its mechanism of action is not well-understood. Here, we investigated the effect of FK506 on TRPC6 in bladder smooth muscle, and explored the possible involvement of TRPC6 in OAB.
Methods: FK506 was injected intraperitoneally into rats in which OAB was induced via BOO, and urodynamic indices were recorded. Read More
PLoS Pathog 2018 Nov 26;14(11):e1007331. Epub 2018 Nov 26.
Section of Virology, Department of Microbial Sciences, Faculty of Health & Medical Sciences, University of Surrey, Guildford, United Kingdom.
HSV1 encodes an endoribonuclease termed virion host shutoff (vhs) that is produced late in infection and packaged into virions. Paradoxically, vhs is active against not only host but also virus transcripts, and is involved in host shutoff and the temporal expression of the virus transcriptome. Two other virus proteins-VP22 and VP16 -are proposed to regulate vhs to prevent uncontrolled and lethal mRNA degradation but their mechanism of action is unknown. Read More
F1000Res 2018 9;7. Epub 2018 Nov 9.
Urology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15213, USA.
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating condition associated with intense pelvic pain and bladder storage symptoms. Since diagnosis is difficult, prevalence estimates vary with the methodology used. There is also a lack of proven imaging tools and biomarkers to assist in differentiation of IC/BPS from other urinary disorders (overactive bladder, vulvodynia, endometriosis, and prostatitis). Read More
Actas Urol Esp 2018 Nov 20. Epub 2018 Nov 20.
Hospital Universitari i Politècnic La Fe, Valencia, España.
Introduction And Objectives: Older patients with overactive bladder under antimuscarinic treatment are especially susceptible to cognitive impairment. The aim was to assess short term changes in cognitive function in elderly patients with overactive bladder treated with transdermal oxybutynin.
Materials And Methods: Observational, retrospective, multicentre study in patients with overactive bladder aged 65-80 years undergoing treatment with transdermal oxybutynin. Read More
J Anxiety Disord 2018 Nov 14;62:1-14. Epub 2018 Nov 14.
Monash Alfred Psychiatry Research Centre, Central Clinical School, Monash University and Alfred Hospital, Level 4, 607, St. Kilda Road, Melbourne, Victoria 3004, Australia; Epworth Centre for Innovation in Mental Health, Epworth HealthCare, 888 Toorak Rd, Camberwell, Victoria 3124, Australia. Electronic address:
Obsessive-compulsive disorder (OCD) is a chronic disease that causes significant decline in the quality of life of those affected. Due to our limited understanding of the underlying pathophysiology of OCD, successful treatment remains elusive. Although many have studied the pathophysiology of OCD through electroencephalography (EEG), limited attempts have been made to synthesize and interpret their findings. Read More
Int Urogynecol J 2018 Nov 22. Epub 2018 Nov 22.
Department of Obstetrics and Gynecology, Section of Urogynecology, Center for Pelvic Health, North Shore University Health System, affiliated with The University of Chicago, Skokie, IL, USA.
Introduction And Hypothesis: We investigated the objective improvements in overactive bladder (OAB) symptoms in patients undergoing percutaneous tibial nerve stimulation (PTNS) and predictive factors of patient satisfaction.
Methods: In this single-center retrospective cohort study at a tertiary urogynecology center, we identified all female patients who underwent PTNS therapy from 1 October 2007 - 1 January 2016 and followed them from their initial visit through medication therapy and PTNS treatments. Patients who tried at least one medication prior to starting PTNS therapy and completed at least one PTNS visit were included. Read More
BMJ Open 2018 Nov 21;8(11):e021889. Epub 2018 Nov 21.
Manchester Metropolitan University, Manchester, UK.
Purpose: To evaluate persistence and adherence of oral pharmacotherapy used in the treatment of overactive bladder (OAB) in a real-world setting.
Materials And Methods: Systematic literature searches of six electronic publication databases were performed to identify observational studies of patients with OAB treated with antimuscarinics and/or mirabegron. Studies obtaining persistence and adherence data from sources other than electronic prescription claims were excluded. Read More
Clin Ther 2018 Nov 26;40(11):1855-1867. Epub 2018 Oct 26.
Quotient Sciences Ltd, Nottingham, United Kingdom.
Purpose: ME-401 is a novel selective inhibitor of phosphatidylinositol 3 kinase p110δ, an enzyme often found overexpressed and overactive in B-cell malignancies. The current study was performed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending oral doses of ME-401 in healthy volunteers.
Methods: This analysis was an open-label, nonrandomized study in healthy male volunteers. Read More
Aging Male 2018 Nov 20:1-6. Epub 2018 Nov 20.
a Department of Palliative Medicine , Juntendo University Graduate School of Medicine , Tokyo , Japan.
This study investigated what sort of effects would occur in terms of sexual function in Japanese patients with benign prostatic hyperplasia (BPH), upon switching from combination therapy with an α1 blocker (AB) and dutasteride (DUT) to combination therapy with tadalafil (TAD) and DUT. The baseline and the 15-item International Index of Erectile Function (IIEF-15), Erection Hardness Score (EHS), International Prostate Symptom Score (IPSS), and Overactive Bladder Symptom Score (OABSS) 3 months after switching to the daily administration of TAD 5 mg/DUT 0.5 mg combination therapy, along with the age, prostatic volume, body mass index (BMI), and past medical history of 49 patients who were treated with AB/DUT as pretreatment, were retrospectively investigated. Read More
Br J Gen Pract 2018 Dec 19;68(677):e852-e859. Epub 2018 Nov 19.
Primary Health Care Service Muntanya de Barcelona, Primary Health Care Barcelona, Catalan Institute of Health, Health Department Barcelona, Barcelona.
Background: Overactive bladder is a composite of lower urinary tract storage symptoms. Pharmacological treatment is widely employed despite markedly modest efficacy data, adverse effects, and costs for the health system.
Aim: To determine the 12-month efficacy of an intervention delivered by GPs on mirabegron revision and, if appropriate, discontinuation of treatment. Read More
Brain Behav 2018 Nov 19:e01164. Epub 2018 Nov 19.
Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Aims: Deep brain stimulation (DBS) is known to dramatically improve motor complications in patients with Parkinson's disease (PD), but its effect on urinary symptoms and health-related quality of life (HRQOL) remains unknown. We aimed to examine the relationship between urinary symptoms and HRQOL in patients with PD who underwent DBS.
Methods: The International Prostate Symptom Score (IPSS) and overactive bladder symptom score (OABSS) were determined to evaluate urinary symptoms in patients with PD who underwent DBS. Read More
Front Immunol 2018 2;9:2537. Epub 2018 Nov 2.
Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China.
Smad7 is an inhibitory Smad and plays a protective role in many inflammatory diseases. However, the roles of Smad7 in rheumatoid arthritis (RA) remain unexplored, which were investigated in this study. The activation of TGF-β/Smad signaling was examined in synovial tissues of patients with RA. Read More
Int Urol Nephrol 2018 Nov 17. Epub 2018 Nov 17.
Department of Urology, Okmeydani Training and Research Hospital, 34384, Sisli, Istanbul, Turkey.
Purpose: The aim of the study was to determine the effect of anticholinergics used for overactive bladder treatment on the sexual function of women.
Methods: Between January 2016 and August 2018, over 18 years old, 216 sexual active women with OAB and 165 healthy women as control group were prospectively enrolled in the study. Five different anticholinergics were used for the treatment. Read More
Handb Exp Pharmacol 2018 Nov 15. Epub 2018 Nov 15.
Section of Pharmacology, Department of Medical Sciences, and National Institute of Neurosciences, University of Ferrara, Ferrara, Italy.
Following identification as the endogenous ligand for the NOP receptor, nociceptin/orphanin FQ (N/OFQ) has been shown to control several biological functions including the micturition reflex. N/OFQ elicits a robust inhibitory effect on rat micturition by reducing the excitability of the afferent fibers. After intravesical administration N/OFQ increases urodynamic bladder capacity and volume threshold in overactive bladder patients but not in normal subjects. Read More
Urologia 2018 Nov 28;85(4):163-168. Epub 2018 Mar 28.
1 Department of Urology, ASL02 Abruzzo, 'S.Pio da Pietrelcina' Hospital, Vasto, Italy.
Objective:: Onabotulinumtoxin-A has been approved for wet overactive bladder refractory to anticholinergics in randomised controlled trials; however, data from real-life practice are scarce. This study was designed to assess the efficacy of intravesical onabotulinumtoxin-A injections, focusing on health status, urinary symptoms and subjective satisfaction.
Methods:: Data from consecutive patients with overactive bladder-refractory to anticholinergics treated with onabotulinumtoxin-A were prospectively collected and analysed. Read More
Res Rep Urol 2018 23;10:169-180. Epub 2018 Oct 23.
Department of Urology, Nara Medical University, Nara, Japan,
Purpose: The aim of this study was to evaluate the chronological changes in lower urinary tract symptoms (LUTSs), disease-related quality of life (QOL), and health-related QOL (HR-QOL) of patients who received intensity-modulated radiotherapy (IMRT).
Patients And Methods: In 121 patients who had received IMRT and were followed up for >2 years, the International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), Expanded Prostate Cancer Index Composite (EPIC), and 8-Item Short-Form Health Survey (SF-8) were used before IMRT, at the halfway point in IMRT, immediately after IMRT, and 1-24 months after the completion of IMRT.
Results: The IPSS and OABSS and the urinary and bowel domains of the EPIC indicated that QOL worsened at the halfway point in IMRT, further worsened more severely immediately after IMRT, and then improved. Read More
Lupus 2018 Nov 12:961203318811605. Epub 2018 Nov 12.
1 Urology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal.
Objective: The objective of this paper is to assess overactive bladder (OAB) symptom bother (SB) and health-related quality of life (HRQL) among patients with systemic lupus erythematosus (SLE) and primary Sjögren syndrome (pSS).
Methods: We recruited adult SLE and pSS patients and two groups of age- and sex-matched controls. We applied the OAB questionnaire-short form (OABq-SF) to all participants to assess SB and HRQL and collected clinical information relevant for OAB. Read More
Int J Urol 2018 Nov 11. Epub 2018 Nov 11.
Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Objectives: To assess whether atherosclerosis is involved in the development of overactive bladder and the function of lower urinary tract after robot-assisted radical prostatectomy.
Methods: The present cohort consisted of 80 consecutive participants. The preoperative cardio-ankle vascular index was used to evaluate the presence of atherosclerosis. Read More
J Sex Med 2018 Nov;15(11):1579-1590
Polyclinic 3, Department of Urology, Vladivostok, Russia.
Introduction: Correction of benign prostatic hyperplasia (BPH) with lower urinary tract (LUT) symptoms (LUTS) is treated with drugs of different pharmacological classes having side effects including suppression of sexual function.
Aim: To assess the effect of simultaneous intake of dutasteride and solifenacin on the reversibility of severe LUTS and sexual function in men with BPH.
Methods: Patients from group A took dutasteride 0. Read More
J Pediatr Urol 2018 Oct 11. Epub 2018 Oct 11.
Centro de Distúrbios Miccionais Na Infância (CEDIMI), Bahiana School of Medicine and Division of Urology, Federal University of Bahia, Salvador, Bahia, Brazil.
Purpose: The purpose of this was to evaluate the efficacy (tolerance and safety) of once-a-week parasacral percutaneous electrical nerve stimulation (PENS) to treat overactive bladder (OAB) in children.
Materials And Methods: This is a prospective case series of children aged 4-14 years who underwent PENS for OAB. Acupuncture needles were used bilaterally and symmetrically at S3 for sacral nerve stimulation (Figure). Read More
J Urol 2018 Sep 5;200(3):503-504. Epub 2018 Jun 5.
J Urol 2018 Sep 5;200(3):502-505. Epub 2018 Jun 5.
J Urol 2018 Sep 5;200(3):477-478. Epub 2018 Jun 5.
J Urol 2018 Sep 5;200(3):477. Epub 2018 Jun 5.
J Urol 2018 Sep 5;200(3):475-476. Epub 2018 Jun 5.
Drugs 2018 Nov;78(17):1835-1839
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
Vibegron is a selective beta 3 adrenergic receptor (βAR) agonist that is being developed in Japan jointly by Kyorin Pharmaceutical Co., Ltd and Kissei Pharmaceutical Co., Ltd and in other regions worldwide (except in several other Asian countries) by Urovant Sciences for the treatment of overactive bladder (OAB). Read More
Case Rep Urol 2018 16;2018:8567436. Epub 2018 Oct 16.
Department of Urogynaecology, King's College Hospital, Denmark Hill, London SE5 9RS, UK.
Urgency is the cornerstone symptom of overactive bladder (OAB) syndrome, which is associated with reduced health-related quality of life (HRQoL) and affects patients with different profiles. We report here three clinical pictures of OAB: a male patient with mixed lower urinary tract symptoms (LUTS), a young woman with comorbidities, and an elderly woman with mixed urinary incontinence. The aim is to analyze the specificities of these real cases, to discuss what would be the most appropriate management, and how treatment with fesoterodine, an antimuscarinic agent with key pharmacological properties, might meet the patients' expectations. Read More